Spero Therapeutics (SPRO) EPS (Basic) (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly EPS (Basic) came in at -$0.16 in Q2 2026, down 441.62% on a YoY basis from $0.05 in Q2 2025, and down 31.02% quarter-over-quarter from -$0.13 in Q1 2026.
Powered by 
Analysis
Spero Therapeutics (SPRO) EPS (Basic) (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has reported EPS (Basic) for 11 consecutive years, with -$0.16 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EPS (Basic) fell 441.62% year-over-year to -$0.16; the trailing twelve-month figure through Jun 2026 stood at $0.1 (up 110.44% YoY), and the FY2025 full-year result was $0.12, up 109.82% from the prior year.
- EPS (Basic) declined to -$0.16 in Q2 2026 per SPRO's latest filing, from -$0.13 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.97 in Q4 2023 and bottomed at -$0.92 in Q1 2022.
- Historically, EPS (Basic) has averaged -$0.13 across 5 years, with a median of -$0.23 in 2023.
- The sharpest annual moves came in 2025 and 2026: EPS (Basic) surged 242.15% in 2025, then slumped 441.62% in 2026.
- Over 5 years, EPS (Basic) stood at $0.71 in 2022, then surged by 36.37% to $0.97 in 2023, then sank by 138.69% to -$0.38 in 2024, then jumped by 242.15% to $0.53 in 2025, then plunged by 130.84% to -$0.16 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.16, -$0.13, and $0.53 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -0.40 |
| 10 | Spero Therapeutics | 67.82 Mn | 17.05 Mn | - | -0.16 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.16 |
| Mar 31, 2026 | -0.13 |
| Dec 31, 2025 | 0.53 |
| Sep 30, 2025 | -0.13 |
| Jun 30, 2025 | -0.03 |
| Mar 31, 2025 | -0.25 |
| Dec 31, 2024 | -0.38 |
| Sep 30, 2024 | -0.33 |
| Jun 30, 2024 | -0.33 |
| Mar 31, 2024 | -0.24 |
| Dec 31, 2023 | 0.97 |
| Sep 30, 2023 | -0.06 |
| Jun 30, 2023 | -0.23 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | 0.71 |
| Sep 30, 2022 | -0.33 |
| Jun 30, 2022 | -0.79 |
| Mar 31, 2022 | -0.92 |
| Dec 31, 2021 | -0.89 |
| Sep 30, 2021 | -0.70 |